Main Article Content


Rheumatoid arthritis (RA) is a chronic form of persistent inflammation. Meanwhile, Substance P is the most associated neuropeptide in neurogenic inflammation and hyperalgesia commonly found in chronic pain. Substance P act by binding to neurokinin-1 receptor. The present study was conducted to evaluate the effect of neurokinin-1 receptor antagonist (CP-96,345) on Adjuvant Induced Arthritis rat model, induced by Complete Freund’s Adjuvant (CFA). The objective is to attenuate neurogenic inflammation which in turn will increase the latency time of hyperalgesia response, decreases neurokinin-1 receptor expression, and inhibits the development of RA in AIA rat model. Rats were intra-articularly injected with CFA 1 hour after the administration of CP-96,345 either by 0.63 µg/gr; 1.25 µg/gr; or 2.5 µg/gr also intra-articularly. Caliper measurements and hot-plate test were performed on day 0, 3, 5, 7, 9, 11, and day 13. Expression of neurokinin-1 receptor in joint tissue were evaluated by immunohistochemistry, and RA progress in joint tissue were observed hystopathologically. CP-96,345 at 2.5 µg/gr significantly increases the latency of hyperalgesia response time on CFA induced rats (p=0.044) and decreased the neurokinin-1 receptor expression in joint tissue (p=0.029) compared to CFA induced rats. There was no significant difference for caliper measurements and RA progress between CFA incduced rats and treated group. Conclusively, CP-96,345 increases the latency of hyperalgesia response time and decreases the NK-1 receptor expression in rat joint but could not inhibit RA progression.


CP-96 345 rheumatoid arthritis hyperalgesia neurokinin-1 CFA

Article Details

How to Cite


  1. Abbas AK, Lichtman AH, Pillai S (2007). Cellular and Molecular Immunology, Philadelphia, Saunders Elsevier, p 5-12
  2. Aggarwal A and Myles A (2013). Inflammatory cascades in autoimmune disease. In: Roy S, Bagchi D, Raychaudhuri SP (eds). Chronic Inflammation, Molecular Pathophysiology, Nutritional and Therapeutic Interventions, Florida, CRC Press, p 213-220
  3. Aloisi AM and Bonifazi M (2006). Sex hormones, central nervous system and pain. Hormones and Behavior 50, 1-7
  4. Austin PJ and Taylor GM (2010). The neuro-immune balance in neuropathic pain: involment of inflammatory immune cells, immune-like glial cells and cytokines. Journal of Neuroimmunology 229, 26-50
  5. Bhatia M and Lau HY (2006). The effect of CP96,345 on the expression of tachykinins and neurokinins receptors in acute pancreatitis. Journal of Pathology 208, 364-371
  6. Bhatia M, Moochhala S, Koh YH (2012). Activation of neurokinin-1 receptors up-regulates substance P and neurokinin-1 receptor expression in murine pancreatic acinar cells. Journal of Molecular Medicine 16, 1582-1592
  7. Bhatia M, Tamizhselvi R, Ramnath RD, Sun J (2009). Role of protein kinase C and phosponoisitide 3-kinase-Akt in substance P-induced proinflammatory pathways in mouse machrophages. The Journal of The Federation of American Societies for Experimental Biology 23, 997-1010
  8. Brain SD and Keeble JE (2004). A role for substance P in arthritis. Neuroscience Letters 361, 176-179
  9. Breedveld FC and Kalden JR (2004). Appropriate and effective management of rheumatoid arthritis. Annals of Rheumatic Disease 63, 627-633
  10. Cases RP, Sanz NG, Palao CM, Montiel AF (2005). Functional aspects and mechanisms of TRPV1 involment in neurogenic inflammation that leads to thermal hyperalgesia. European Journal of Physiology 451, 151-159
  11. Davis AJ and Perkins MN (1996). Substance P and capsaicin-induced mechanical hyperalgesia in the rat knee joint; the involment of bradykinin B1 and B2 receptors. British Journal of Pharmacology 118, 2206-2212
  12. Dickenson A (1999). The roles of spinal receptors in nociceptive responses. In: Brain SD and Moore PK (eds). Pain and Neurogenic Inflammation, New York, Springer, p 23-38
  13. Emery P (2011). Pocket Reference to Early Rheumatoid Arthritis, London, Springer Healtcare Ltd, p 3-51
  14. Geppeti P, Materazzi S, Nicoletti P, Trevisani M (2006). In vivo models of neurogenic inflammation. In: Stevenson CS, Marshall LA, Morgan DW (eds). In Vivo Models of Inflammation, Vol 1, Switzerland, Birkhäuser Basel, p 121-135
  15. Gerhardt WK abd Schmidtko A (2011). A novel signaling pathway that modulates inflammatory pain. The Journal of Neuroscience 3, 798-800
  16. Hong SK, Han JS, Min SS, Hwang JM, Kim YI, Na HS, Yoon YW, Han HC (2002). Local neurokinin-1 receptor in the knee joint contributes to the induction, but not maintenance, of arthritic pain in the rat. Neuroscience Letters 322, 21-24
  17. Johnson K and Bolay H (2005). Neurogenic inflammatory mechanisms. In: Olesen J, Tfelt-Hansen P, Welch K, Goadsby PJ, Ramadan N. Headaches, Philadelphia, Lippincot Williams & Wilkins, p 311
  18. Krause JE, Takeda Y, Hershey AD (1992). Structure, functions, and mechanisms of substance P receptor action. Journal of Investigative Dermatology 98, 2S-7S
  19. Lee YC and Hasset AL (2011). Pain in rheumatoid arthritis. Available from Accessed 10 November, 2014
  20. Lembeck F, Donnerer J, Tsuchiya M, Nagahisa A (1992). The non-peptide tachykinin antagonist, CP-96,345 is a potents inhibitor of neurogenic inflammation. British Journal of Pharmacology 105, 527-530
  21. Nessler S, Stadelmann C, Bittner A, Schlegel K, Gronen F, Brueck W, Hemmer B, Sommer N (2006). Suppression of autoimmune encephalomyelitis by a neurokinin-1 receptor antagonist - a putative role for substance P in CNS inflammation. Journal of Neuroimmunology 179, 1-8
  22. O'Connor TM, O'Connell J, O'Brien DI, Goode T, Bredin CP, Shanahan F (2004). The role of substance p in inflammatory disease. Journal of Cellular Physiology 201, 167-180
  23. Peterson M, Svärdsudd K, Appel L, Engler H, Aarnio M, Gordh T, Långström B, Sörensen J (2013). PET-scan shows peripherally increased neurokinin 1 receptor availability in chronic tennis elbow: visualizing neurogenic inflammation? PloS ONE 8, e75859
  24. Pothoulakis C, Castagliuolo I, Lamont JT, Jaffer A, O'Keane JC, Snider RM, Leeman SE (1994). CP-96,345, a substance P antagonist inhibits rat intestinal responses to clostridium difficile toxin A but not cholera toxin. Proceedings of the National Academy of Sciences 91, 947-951
  25. Reedquist KA and Tak PP (2012). Signal transduction pathways in chronic inflammatory autoimmune disease: small GTPases. The Open Rheumatology Journal 6, 259-272
  26. Ren K and Dubner R (2010). Interactions between the immune and nervous systems in pain. Nature Medicine 16, 1267-1276
  27. Richardson JD and Vasko MR (2002). Cellular mechanisms of neurogenic inflammation. The Journal of Pharmacology and Experimental Therapeutics 302, 839-845
  28. Shrikhande SV, Friess H, di Mola FF, Tempia-Caliera A, Garcia JRC, Zhu Z, Zimmermann A, Büchler MW (2001). NK-1 receptor gene expression is related to pain in chronic pancreatitis. Pain 91, 209-217
  29. Snider RM, Longo KP, Drozda SE, Lowe JA, Leeman SE (1991). Effect of CP-96,345 a nonpeptide substance P receptor antagonist on salivation in rats. Proceedings of National Academy of Sciences 88, 10042-10044
  30. Teodoro FC, TroncoJr MF, Zampronio AR, Martini AC, Rae GA, Chichorro JG (2013). Peripheral substance P and neurokinin-1 receptors have a role in inflmammatory and neurophatic orofacial pain models. Neuropeptides 47, 199-206
  31. Tsuda M, Masuda T, Tozaki-Saitoh H, Inoue K (2013). P2X4 receptors and neuropathic pain. Frontiers in Cellular Neuroscience 7, 167-172
  32. Vashist H, Gupta A, Jindal A, Jalhan S (2012). animal models for arhtritis-a review. International Journal of recent Advances in Pharmaceutical Research 2, 20-25
  33. Xu XJ, Dalsgaard CJ, Maggi CA, Wiesenfeld-Hallin Z (1992). NK-1, but not NK-2, tachykinin receptors mediate plasma extravasation induced by antidromic C-fiber stimulation in rat hindpaw: demonstrated with the NK-1 antagonist CP-96,345 and the NK-2 antagonist men 10207. Neuroscience Letters 139, 249-252

Most read articles by the same author(s)